Superlab Suisse Unveils Advanced Laboratory Facility in Basel

Superlab Suisse, a leading provider of innovative laboratory and research spaces, has announced the grand opening of its newest facility in Basel, making it the largest private lab space in Switzerland. This cutting-edge facility, set to open in July 2024, follows the success of Superlab Suisse's Lausanne location and marks a significant milestone in providing research infrastructure to Switzerland's dynamic life sciences sector.

With a strategic partnership with Swiss Prime Site, Superlab Suisse aims to create substantial commercial opportunities in Basel, a renowned biotechnology hub home to over 700 companies, including pharmaceutical giants Novartis and Roche. The new facility, located within the bustling Stücki Park, neighbors prominent entities such as Tech Park Basel, Lonza, Medartis, NBE, and Boehringer Ingelheim.

The facility offers ready-to-use laboratory spaces equipped with the latest technology and essential operational support services, allowing research teams to focus their resources on scientific endeavors rather than lab operations. Spanning over 4770 square meters, it promises to be a nucleus of scientific collaboration and breakthrough, redefining laboratory services in Basel.

Xi Zhang, CEO of Superlab Suisse, expressed enthusiasm about the new launch, stating, "We are thrilled to bring Superlab Suisse's innovative platform to Basel, the city of Pharma. Our holistic solution frees scientists from operations headaches, so they can save time and focus on science. We service, you discover."

Historically, life sciences and biotech companies have faced significant financial barriers to innovation due to the high costs of building and operating laboratory spaces. Universities have typically been the only viable option, with lab construction requiring substantial upfront investments that divert attention away from research. Superlab Suisse's serviced BSL1 and BSL2 labs address this issue by providing a new industry standard of lab solutions. Companies based in Basel also gain access to facilities in Lausanne and other locations, eliminating the hurdles of lab construction and operation.

One of the first companies to secure space at the new facility is Skyhawk Therapeutics, which has recently announced a research collaboration with Ipsen focusing on RNA targeting in rare neurological diseases. Additionally, Superlab Suisse plans to open a third site in Zurich Schlieren in March 2025, catering to the diverse needs of start-ups, spin-offs, and established companies in the life sciences sector. This expansion will further solidify Superlab Suisse's position as a leader in laboratory-as-a-service solutions.

The broader vision of Superlab Suisse includes expanding to more cities across Europe, the US, and Asia, embodying a borderless lab concept to benefit the global life sciences community. Dr. Rajwinder Lehal, CEO of biotech business Cellestia, praised the initiative, stating, "Superlab is exactly the place which the scientific community needs, where we can concentrate on our work without being distracted by construction or operation." Emmanuel Savioz, CEO & Chairman of Tigen Pharma, echoed this sentiment, highlighting the vibrant scientific community and state-of-the-art facilities provided by Superlab Suisse.

Superlab Suisse AG offers innovative laboratory solutions through its "Lab as a Service" business concept, empowering companies in the biotech, pharma, and medtech sectors to focus on research and innovation. Swiss Prime Site, the largest real estate company in Switzerland, plays a crucial role in this partnership by providing valuable real estate and commercial property management expertise.

For further details, visit Superlab Suisse's website or the source version on NewsDirect.